Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- The Richard King Mellon Foundation has committed up to $25 million to launch Rare Ventures, a first-of-its-kind venture philanthropy platform for accelerating rare disease therapies. - The initiative unites Carnegie Mellon University, the University of Pittsburgh, UPMC, Stanford Medicine, ElevateBio, and the EB Research Partnership to combine AI, clinical research, and therapeutic development. - More than 400 million people worldwide live with a rare disease, yet approximately 95% of the 10,000+ rare diseases lack an approved treatment. - Rare Ventures builds on EBRP's 14-year track record, which helped fund over 180 research projects and contributed to three FDA-approved therapies for epidermolysis bullosa.
- UPMC researchers successfully weaned four liver transplant patients off all immunosuppressive drugs for over three years using donor-derived regulatory dendritic cells. - The phase I/IIa trial achieved a 37.5% tolerance rate among eligible patients, significantly higher than the historical 13% rate in standard care recipients. - The innovative approach involves infusing recipients with donor immune cells one week before transplantation to train the immune system to accept the new organ. - Results from the 13-patient study justify larger randomized controlled trials to validate this potential breakthrough in transplant medicine.
- A two-year exploratory clinical trial from the University of Pittsburgh found that low-dose oral lithium may help slow the decline of verbal memory in older adults with mild cognitive impairment. - The study showed particularly encouraging results among participants positive for amyloid beta, one of the hallmark biomarkers of Alzheimer's disease. - Researchers confirmed that low-dose lithium was safe and well tolerated in older adults when carefully monitored, addressing safety concerns for aging populations. - The findings support the need for a larger, more definitive clinical trial using blood-based biomarkers to identify individuals most likely to benefit from lithium treatment.
- GenSight Biologics received FDA authorization and IRB approval for expanded access treatment of one patient with its gene therapy GS010/LUMEVOQ® at the University of Pittsburgh School of Medicine in November 2025. - The authorization represents the first regulatory approval for the candidate since the company withdrew its European marketing authorization application in 2023. - GS010/LUMEVOQ® targets Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial genetic disease that causes irreversible vision loss and legal blindness in teens and young adults. - The company is preparing for a pivotal Phase III study RECOVER in H2 2026 while completing technology transfer to manufacturing partner Catalent to produce new batches for clinical and early access needs.
- Samsung Electronics signed an agreement to acquire Xealth, a digital health platform spun out of Providence in 2017 that serves over 500 hospitals and partners with 70+ digital health companies. - The acquisition aims to bridge consumer wellness data from Samsung's wearables with clinical decision-making through Xealth's centralized digital health platform. - Xealth enables healthcare providers to digitally order and monitor remote patient monitoring, digital therapeutics, and mHealth apps while streamlining vendor integration and data analytics. - The deal is expected to close later this year following regulatory approval and represents Samsung's strategic move to advance connected care in healthcare systems.
- Abridge raised $300 million in Series E funding led by Andreessen Horowitz, bringing its valuation to $5.3 billion for its ambient listening technology that automates clinical documentation. - The AI-powered platform serves over 150 health systems including Kaiser Permanente, UPMC, and Sutter Health, generating clinical notes from medical conversations across 55 specialties and 28 languages. - The company reports significant clinical impact with 60-70% reduction in burnout and over 90% clinician retention rate, while projecting support for more than 50 million medical conversations in 2025. - This funding round follows a $250 million raise in February, representing one of the most substantial health tech deals of 2024 as AI scribes gain rapid adoption to address clinician burnout.
- New research indicates that exposure to long-wavelength red light can significantly reduce blood clot formation in both humans and mice, offering a potential new therapeutic avenue. - The study found that mice exposed to red light had nearly five times fewer blood clots compared to those exposed to blue or white light, with consistent activity and sleep patterns. - Analysis of cataract surgery patients revealed that those with blue light-filtering lenses had a lower risk of blood clot formation, particularly benefiting cancer patients. - Researchers are developing red light goggles for clinical trials to assess the efficacy of targeted red light treatment in reducing blood clot risk in high-risk patients.
• Carta Healthcare acquired Realyze Intelligence to enhance its AI-powered platform for clinical data analysis, particularly in oncology. • Realyze Intelligence's AI rapidly analyzes EHR data to match cancer patients with clinical trials, reducing the time from hours to seconds. • The integration aims to improve patient outcomes by accelerating clinical trial enrollment and optimizing care pathways through better data utilization. • Carta Healthcare's expanded platform will reduce costs and labor for clinical data registry abstraction, research, and quality performance programs.
- A clinical trial showed that adding pembrolizumab to standard treatment significantly improved disease-free survival in patients with advanced soft tissue sarcoma. - The two-year disease-free survival rate increased from 52% in the control group to 67% in the group receiving pembrolizumab plus standard care. - While adverse events were more frequent in the pembrolizumab group, there were no treatment-related deaths, suggesting it may be a less toxic option than chemotherapy. - Researchers hope the findings will lead to broader use of immunotherapy in treating soft tissue sarcoma and ultimately improve overall survival.
- The University of Pittsburgh has been awarded $100 million by the Department of Defense to continue and expand its trauma research through the LITES Network. - The LITES Network will launch the PREEVEnT trial to assess early plasma administration in burn patients compared to the standard of care for improved outcomes. - The LITES Network has completed five studies, with four ongoing clinical trials, aimed at transforming trauma care practices and saving lives. - The collaborative effort involves multiple trauma centers and focuses on addressing critical gaps in pre-hospital trauma care research and innovation.
